Vnitr Lek 2023, 69(4):254-260 | DOI: 10.36290/vnl.2023.048

Osteomalacia

Jan Rosa
Osteocentrum Affidea Praha, Lékařská fakulta Univerzity Karlovy v Hradci Králové

Osteomalacia with characteristic histomorphometric, radiographic, laboratory and clinical features is a prominent syndrome of disturbed bone mineralisation in adulthood. From an etiological point of view, osteomalacia is usually caused by substrate (calcium, phosphate) deficiency, presence of excess mineralization inhibitors or deficiency or ineffectivness of mineralization facilitator (vitamin D). In proportion to the high number of congenital and acquired causes of osteomalacia, its clinical and laboratory picture is heterogeneous and rarely fully expressed. The treatment of a particular case is determined by the cause of osteomalacia and may (but does not necessarily) include correction of the underlying disease, administration of calcium and various forms of vitamin D, as well as orthopaedic interventions. For some of the hereditary forms, biological or replacement therapy is prospectively available. The article attempts to cover the whole range of osteomalacia variants, mentioning a fact discussed only in recent years - the occurrence of oligosymptomatic, incompletely expressed forms.

Keywords: kostní matrix, kostní minerál, mineralizace, osteoid, osteomalacie.

Accepted: May 31, 2023; Published: June 22, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rosa J. Osteomalacia. Vnitr Lek. 2023;69(4):254-260. doi: 10.36290/vnl.2023.048.
Download citation

References

  1. Zhou, R, Guo Q, Xiao Y, et al. Endocrine role of bone in the regulation of energy metabolism. Nature Bone Research. 2021;9:25. Go to original source... Go to PubMed...
  2. Boivin G, Meunier PJ. The mineralization of bone tissue: a forgotten dimension in osteoporosis research. Osteoporos Int. 2003;14(Suppl 3):S19-S24. Go to original source...
  3. Yadav MC, Simão AMS, Narisawa S, et al. Loss of skeletal mineralization by the simultaneous ablation of PHOS­‑PHO1 and alkaline phosphatase function: a unified model of the mechanismsof initiation of skeletal calcification. J Bone Miner Res. 2011;26:286-297. Go to original source... Go to PubMed...
  4. Hinson J, Raven P, Chew S. Hormonal regulation of plasma calcium and calcium metabolism. In: The Endocrine System (Second Edition). 2010;147-159. Go to original source...
  5. Jannin A, Kerlan V, Desailloud R. Endocrinology of bone mineralization: An update. Annales d'Endocrinologie. 2022;83:46-53. Go to original source... Go to PubMed...
  6. Bhan A, Qiu S, Rao SD. Bone histomorphometry in the evaluation of osteomalacia. Bone Rep. 2018;8:125-134. Go to original source...
  7. Dempster DW, Compston JE, Drezner MK, et al. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 2013;28:2-17. Go to original source... Go to PubMed...
  8. Fukumoto S, Ozono K, Michigami T, et al. Pathogenesis and diagnostic criteria for rickets and osteomalacia-proposal by an expert panel supported by the Ministry of Health, Labour and Welfare, Japan, the Japanese Society for Bone and Mineral Research, and the Japan Endocrine Society. J Bone Miner Metab. 2015;33:467-473. Go to original source... Go to PubMed...
  9. Finch PJ, Ang L, Eastwood JB, Maxwell JB. Clinical and histological spectrum of osteomalacia among Asians in south London. Q J Med. 1992;302:439-448.
  10. Priemel M, von Domarus C, Klatte TO, et al. Bone Mineralization Defects and Vitamin D Deficiency: Histomorphometric Analysis of Iliac Crest Bone Biopsies and Circulating 25-Hydroxyvitamin D in 675 Patients. J Bone Mineral Res. 2010; 25:305-312. Go to original source... Go to PubMed...
  11. Smerdon GT. Daniel Whistler and the English Disease: A Translation and Biographical Note. J Hist Med Allied Sci. 1950;5:397-415. Go to original source...
  12. Dunn PN. Francis Glisson (1597-1677) and the "discovery" of rickets. Arch Dis Child Fetal Neonatal Ed. 1998;78:F154-F155. Go to original source...
  13. Newton G. Diagnosing Rickets in Early Modern England: Statistical Evidence and Social Response. Soc History Medicine. 2021;35:566-588. Go to original source... Go to PubMed...
  14. Wheeler BJ, Snoddy AM, Munns C, et al. A Brief History of Nutritional Rickets. Front Endocrinol. 2019;10:795. Go to original source... Go to PubMed...
  15. Stoddard CS. Osteomalacia. California State Journal of Medicine. 1905;3:155-156.
  16. Padidela R, Nilsson O, Makitie O, et al. The international X­‑linked hypophosphataemia (XLH) registry (NCT03193476): rationale for and description of an international, observational study. Orphanet Journal of Rare Diseases. 2020;15:172. Go to original source... Go to PubMed...
  17. Conti F, Ciullini L, Pugliese G. Hypophosphatasia: clinical manifestation and burden of disease in adult patients. Clin Cases Mineral Bone Metabol. 2017;14:230-234. Go to original source... Go to PubMed...
  18. Lips P, de Jongh RT. Vitamin D deficiency in immigrants. Bone Reports. 2018;9:37-41. Go to original source... Go to PubMed...
  19. Yousef S, Manuel D, Colman I, et al. Vitamin D Status among First­‑Generation Immigrants from Different Ethnic Groups and Origins: An Observational Study Using the Canadian Health Measures Survey. Nutrients. 2021;13:2702. Go to original source... Go to PubMed...
  20. Hordon LD, Peacock M. Osteomalacia and osteoporosis in femoral neck fracture. Bone Miner. 1990;11:247-59. Go to original source... Go to PubMed...
  21. Kumar K, Bhayana H, Vaiphei K, et al. Coexistence of Osteomalacia in Osteoporotic Hip Fractures in More Than 50 Years Age Group. Indian Journal of Orthopaedics. 2021;55:614-620.Další literatura u autora a na www.casopisvnitrnilekarstvi.cz Go to original source... Go to PubMed...
  22. Mackay H, May QI. Rickets Resistant to Vitamin D: Healing with Very Heavy Dosage of Vitamin D, Fluctuations in Vitamin D Requirement, Development of Hypercalcaemia. Proc R Soc Med. 1945;38:565-566. Go to original source...
  23. Dent CE, Harris HJ. Hereditary forms of rickets and osteomalacia. J Bone Joint Surg Br. 1956;38:204-226. Go to original source... Go to PubMed...
  24. Minisola S, Coangelo L, Pepe J, et al. Osteomalacia and Vitamin D Status: A Clinical Update 2020. JBMR® Plus (WOA) 2021;5:e10447. Go to original source... Go to PubMed...
  25. Friedman HZ, Langman CB, Favus MJ. Vitamin D metabolism and osteomalacia in cystic fibrosis. Gastroenterology. 1985;88:808-813. Go to original source... Go to PubMed...
  26. Gohil A, Imel EA. FGF23 and associated disorders of phosphate wasting. Pediatr Endocrinol Rev. 2019;17:17-34. Go to PubMed...
  27. Florenzano P, Gafnia RI, Collins MT. Tumor­‑induced osteomalacia. Bone Reports. 2017;7:90-97. Go to original source... Go to PubMed...
  28. Minisola S, Fukumoto S, Xia W, et al. Tumor­‑induced Osteomalacia: A Comprehensive Review. Endocrine Reviews. 2023;44:323-353. Go to original source... Go to PubMed...
  29. Schmidt T, Mussawy H, Rolvien T, et al. Clinical, radiographic and biochemical characteristics of adult hypophosphatasia. Osteoporos Int. 2017;28:2653-2662. Go to original source...
  30. Holick MF, Binkley NC, Bischoff­‑Ferrari Ham, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96:1911-1930. Go to original source... Go to PubMed...
  31. Bischoff­‑Ferrari HA, Shao A, Dawson­‑Hughes B, et al. Benefit­‑risk assessment of vitamin D supplementation. Osteoporos Int. 2010;21:1121-1132. Go to original source...
  32. Motosuneya T, Asazuma T, Yasuoka H, Tsuji T, Fujikawa K. Severe kyphoscoliosis associated with osteomalacia. Spine J 2006;6:587-590. Go to original source... Go to PubMed...
  33. Saghafi M, Azarian A, Hashemzadeh K, Sahebari M, Rezaieyazdi Z. Bone densitometry in patients with osteomalacia: is it valuable? Clin Cas Mineral Bone Metabol. 2013;10:180-182.
  34. Kärkkäinen M, Tuppurainen M, Salovaara K, et al. Effect of calcium and vitamin D supplementation on bone mineral density in women aged 65-71 years: a 3-year randomized population­‑based trial (OSTPRE­‑FPS). Osteoporos Int 2010;21:2047-2055. Go to original source... Go to PubMed...
  35. Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta­‑analysis. Lancet. 2014;383:146-155. Go to original source...
  36. Dawson­‑Hughes B, Harris SS, Krall EA, Dalllal GE. Effect of Calcium and Vitamin D Supplementation on Bone Density in Men and Women 65 Years of Age or Older. N Engl J Med. 1997;337:670-676. Go to original source... Go to PubMed...
  37. Bergman GJE, Fan T, McFetridge JT, Sen SS. Efficacy of vitamin D3 supplementation in preventing fractures in elderly women: A meta­‑analysis. Curr Med Res Opinion. 2010;26:1193-1201. Go to original source... Go to PubMed...
  38. Schweth V, Trummer C, Pandi M, et al. Effects of Vitamin D Supplementation on Bone Turnover Markers: A Randomized Controlled Trial. Nutrients. 2017,9:432; doi:10.3390/nu9050432. Go to original source... Go to PubMed...
  39. Malabanan A, Veronikis IE, Holick MF Redefining vitamin D insufficiency. Lancet 1998; 351:805-806. Go to original source... Go to PubMed...
  40. Bleizgys, A. Vitamin D Dosing: Basic Principles and a Brief Algorithm (2021 Update). Nutrients. 2021;13:4415. Go to original source... Go to PubMed...
  41. Braslavská D, Monhart Z. Když vitamin D škodí. Prezentováno na XXVIII. Kongresu České internistické společnosti ČLS JEP 20.-23. 10. 2021, Brno, sborník abstrakt str. 46.
  42. Camacho PM, Mazhari AM, Wilczynski C, et al. Adult hypophosphatasia treated with teriparatide: Report of 2 patients and review of the literature. Endocr Pract 2016;22:941-950. Go to original source... Go to PubMed...
  43. Polyzos AS, Tournis S, Goulas A, Kollia P, Whyte MP. Adult hypophosphatasia treated with reduced frequency of teriparatide dosing. J Muskuloskelet Neuronal Interact. 2021;21:584-589.
  44. Sasigarn A Bowden SA, Foster BL. Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy. Drug Design, Development and Therapy. 2018:123147-3161. Go to original source...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.